The review for the second quarter of 2024 provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP).
As part of its manufacturing sites modernization program, Binnopharm Group, a leading Russian pharmaceutical company, has launched a new suppository production line at the Binnopharm...
The quarterly review provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP)...
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease.
The product was developed as part of the state strategy for increasing the population's life expectancy and quality of life and improving medicine availability.
The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus.